ClinConnect ClinConnect Logo
Search / Trial NCT04087642

CREDE Study: Intraoperative Crede Manoeuver Compared to Preoperative Prolapse Reduction Stress Test to Predict Postoperative de Novo Stress Urinary Incontinence (PONSUI) at the Time of Pelvic Organ Prolapse (POP) Surgery

Launched by MCGILL UNIVERSITY HEALTH CENTRE/RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE · Sep 11, 2019

Trial Information

Current as of July 05, 2025

Recruiting

Keywords

ClinConnect Summary

The CREDE Study is a clinical trial designed to find the best way to predict and prevent a condition called de Novo Stress Urinary Incontinence (PONSUI) in women undergoing surgery for pelvic organ prolapse (POP). In this study, researchers are comparing two methods: one that happens during the surgery (the intraoperative Crede maneuver) and another that takes place before the surgery (the preoperative cough stress test). The goal is to see which method better helps to identify women at risk of developing urinary incontinence after their surgery, and how this affects their quality of life.

To participate in the CREDE Study, women must be between the ages of 65 and 74 and have a specific type of pelvic organ prolapse that needs surgical treatment. Certain women may not be eligible, such as those who have a history of stress urinary incontinence, have had previous surgeries for incontinence, or are currently pregnant. If you join the study, you will undergo either the intraoperative or the preoperative test, and then you will be followed up for six months to see how you are doing. This trial is important because it aims to gather information that will help improve future treatments for women facing these issues.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Anterior, uterine or apical prolapse with a POP-Q stage II or more requiring surgical correction
  • Exclusion Criteria:
  • Stress urinary incontinence (SUI) on history
  • Previous anti-incontinence surgery
  • Pregnancy
  • Prior urethral repair surgery (diverticulum, fistula)
  • Women who do not speak or read English or French
  • Isolated posterior compartment prolapse
  • Geographic location preventing women to come to 6 week and 6 month appointments

About Mcgill University Health Centre/Research Institute Of The Mcgill University Health Centre

The McGill University Health Centre (MUHC) and the Research Institute of the McGill University Health Centre (RI-MUHC) are leading institutions in clinical research and healthcare innovation. With a commitment to advancing medical knowledge and improving patient outcomes, the MUHC integrates cutting-edge research with high-quality patient care. The RI-MUHC fosters a collaborative environment where multidisciplinary teams engage in transformative research across various fields, including oncology, neurology, and cardiovascular health. By leveraging state-of-the-art facilities and a robust network of clinical expertise, both entities strive to translate scientific discoveries into effective treatments, ultimately enhancing the quality of life for patients locally and globally.

Locations

Montréal, Quebec, Canada

Montreal, Quebec, Canada

Patients applied

0 patients applied

Trial Officials

Maryse Larouche, MD, MPH

Principal Investigator

St. Mary's Research Centre and RI-MUHC

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials